Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
EMvision Medical Devices Ltd. (EMV) vs. iShares MSCI Australia ETF (EWA)
EMvision Medical Devices Ltd. Business Overview & Revenue Model
EMvision Medical Devices Ltd. Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 8.06M | 11.22M | 6.97M | 4.36M | 1.70M | 1.55M | Gross Profit |
| 8.06M | 11.22M | 6.63M | 4.12M | 1.58M | 1.55M | EBIT |
| -5.27M | -1.61M | -10.93M | -10.47M | -10.18M | -5.11M | EBITDA |
| -5.75M | -2.09M | -3.49M | -7.84M | -9.56M | 0.00 | Net Income Common Stockholders |
| -6.19M | -2.73M | -3.87M | -6.11M | -8.40M | -3.48M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 8.48M | 18.67M | 9.97M | 6.80M | 9.69M | 5.41M | Total Assets |
| 11.24M | 23.97M | 11.52M | 8.51M | 10.77M | 6.01M | Total Debt |
| 2.97M | 2.90M | 3.04M | 737.86K | 213.17K | 0.00 | Net Debt |
| -5.51M | -15.70M | -6.93M | -6.06M | -9.48M | -5.41M | Total Liabilities |
| 5.53M | 5.46M | 6.40M | 1.43M | 720.01K | 489.73K | Stockholders Equity |
| 5.71M | 18.52M | 5.12M | 7.08M | 10.05M | 5.52M |
| Cash Flow | Free Cash Flow | ||||
| -9.60M | -6.29M | 646.86K | -3.97M | -4.62M | -3.26M | Operating Cash Flow |
| -9.50M | -5.99M | 834.15K | -3.78M | -4.49M | -3.26M | Investing Cash Flow |
| -289.24K | -302.41K | -187.29K | -191.12K | -127.25K | 0.00 | Financing Cash Flow |
| 14.99M | 15.00M | 2.52M | 1.08M | 8.90M | 4.28M |
EMvision Medical Devices Ltd. Technical Analysis
EMvision Medical Devices Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
50 Neutral | $68.93M | ― | -51.08% | ― | 10.22% | -2.94% | |
48 Neutral | AU$151.79M | ― | -58.61% | ― | ― | -74.88% | |
38 Underperform | AU$1.53B | ― | -38.95% | ― | ― | -16.77% | |
37 Underperform | AU$19.87M | ― | -130.18% | ― | 3.37% | 47.32% |
EMvision Medical Devices Ltd. Corporate Events
EMVision Medical Devices Limited has appointed Carmel Monaghan as an Independent Non-Executive Director. Ms. Monaghan, currently the CEO of Ramsay Healthcare Australia, brings extensive experience in healthcare leadership, corporate strategy, and marketing. Her appointment comes as EMVision is undergoing pivotal trials for regulatory clearance, positioning the company for growth and commercialization of its neurodiagnostic products. This strategic move is expected to enhance EMVision’s capabilities in addressing unmet patient needs, particularly in the areas of stroke and traumatic brain injury, which are significant global health challenges.
EMVision Medical Devices Ltd announced the appointment of Carmel Monaghan as a director effective June 5, 2025. The notice indicates that Monaghan currently holds no securities in the company, suggesting a focus on governance and strategic oversight rather than financial interest. This appointment may influence the company’s strategic direction and strengthen its leadership team, potentially impacting its market positioning and stakeholder relations.
EMVision Medical Devices Ltd has announced the activation of two additional sites for its pivotal trial of the emu™ bedside brain scanner, with Mount Sinai in New York and Liverpool Hospital in Sydney joining the study. These activations bring the total to five sites, with a sixth to follow, as part of efforts to validate the device’s diagnostic performance for FDA De Novo clearance. The trial aims to demonstrate the scanner’s potential to improve stroke diagnosis and treatment outcomes by enabling rapid differentiation of stroke types at the point-of-care.
EMVision Medical Devices Ltd has announced significant improvements in its AI-powered ‘ischemia or not’ diagnostic algorithm, achieving 95% sensitivity and 80% specificity in recent tests. These enhancements are part of the company’s ongoing innovation efforts and are expected to support the validation and potential FDA clearance of their emu™ brain scanner device, which could have substantial implications for stroke diagnosis and treatment.
EMVision Medical Devices Ltd has commenced a pivotal clinical trial for its emu™ bedside brain scanner, aiming for FDA De Novo clearance, marking a significant milestone in the development of its neurodiagnostic technology. The company is also advancing its First Responder device, which has successfully undergone aeromedical testing, and is preparing for further usability studies. With a strong cash reserve and support from the Australian Stroke Alliance grant, EMVision is well-positioned to continue its innovation and market engagement efforts, including showcasing its technology at industry events.
EMvision Medical Devices Ltd announced the cessation of Geoff Pocock as a director, effective April 15, 2025. This change in leadership may impact the company’s strategic direction and stakeholder relations, as directors play a crucial role in guiding company operations and maintaining investor confidence.
EMVision Medical Devices Ltd has commenced a pivotal validation trial for its emu™ bedside brain scanner, aiming to secure FDA De Novo clearance. The trial, involving sites in Australia and the US, seeks to demonstrate the device’s effectiveness in detecting haemorrhages in stroke patients. With an enrolment period of 6-12 months, the trial will enroll 300 participants across six sites, with the goal of achieving a haemorrhage detection sensitivity and specificity of over 80%. This trial is critical for the company’s market positioning as it supports the FDA clearance process and sets the stage for the emu™ device to become a predicate for future products, such as a First Responder device. Concurrently, EMVision is conducting a Continuous Innovation Study to enhance its AI algorithms and device features, further solidifying its competitive edge in stroke diagnostics.
EMVision Medical Devices Ltd has successfully tested its First Responder Proof-of-Concept device in an aeromedical environment, marking a significant milestone in its development. The device, designed to enhance stroke and traumatic brain injury care, demonstrated resilience in challenging conditions and is part of a broader initiative involving collaborations with the Royal Flying Doctor Service and the Australian Stroke Alliance. This initiative aims to improve patient outcomes in rural and remote areas by providing timely neurodiagnostic capabilities, thereby addressing a critical unmet need in emergency medical care.